Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer
511 Background: Based on interim results of the prospective, randomized, multicenter Chemo N0 trial and an EORTC pooled analysis (n = 8,377), ASCO and AGO guidelines recommend invasion markers uPA/PAI-1 for risk assessment in N0 breast cancer. Methods: We present final analysis of the Chemo N0 trial (recruitment 1993–1998; n = 647; 12 centers) with 113 (5–167) months median follow-up. Patients (pts) with low tumor levels of uPA and PAI-1 (n = 283) were observed. Of 364 patients with high uPA and/or PAI-1, 242 were randomized to CMF chemotherapy (n = 117) vs. observation (n =125); 122 pts decided for or against CMF on their own. External quality assurance provided good ELISA standardization in 5 participating laboratories. Results: The actuarial 10-year recurrence rate (without any adjuvant systemic therapy) for high uPA/PAI-1 pts in the combined (randomized and not randomized) observation group was 23.0%, in contrast to only 12.9% in those with low uPA/PAI-1 (p = 0.011, log rank). High-risk pts randomized for CMF had a 26.0% lower estimated probability of disease recurrence than high-risk pts randomized for observation (intention-to-treat analysis: HR 0.74 (0.44–1.27); p = 0.28, log rank). In per-protocol analysis, the treatment benefit was significant: HR 0.48 (0.25–0.88), p = 0.019, adjusted for tumor stage and grading in Cox regression for DFS; for OS, HR was 0.64 (0.35–1.19); p = 0.162, adjusted for tumor stage and grading in Cox regression. Conclusions: Chemo N0 is the first prospective biomarker-based therapy trial in early breast cancer defining a patient group achieving good long-term DFS without any adjuvant therapy. This trial demonstrates that, using a standardized uPA/PAI-1 ELISA, about half of N0 pts, classified as low-risk, could be spared chemotherapy, while high-risk pts benefit from adjuvant chemotherapy. These 10-year results validate the long-term prognostic and predictive impact of uPA/PAI-1 at highest level of evidence (LOE I) and support their guideline-based routine use for risk-adapted individualized therapy decisions in N0 breast cancer. The ongoing NNBC-3 trial is evaluating optimal chemotherapy for uPA/PAI-1 high-risk patients. [Table: see text]